Search | WHO COVID-19 Research Database

Immune Responses in Pediatric COVID-19 Patients: Are They Protected?

Fazolo, T.; Lima, K.; Fontoura, J. C.; de Souza, P. O.; Hilario, G.; Zorzetto, R.; Rodrigues, L.; Pscheidt, V. M.; Neto, J. D. F.; Haubert, A. F.; Gambin, I.; Oliveira, A. C.; Mello, R. S.; Gutierres, Mdbe, Gassen, R. B.; Coimbra, L. D.; Borin, A.; Marques, R. E.; Modena, J. L.; Sartor, I. T. S.; Zavaglia, G. O.; Fernandes, I. R.; Nakaya, H. I.; Varela, F. H.; Polese-Bonatto, M.; Borges, T. J.; Callegari-Jacques, S. M.; da Costa, M. S. C.; Schwartz, J. D.; Scotta, M. C.; Stein, R. T.; Bonorino, C..

Pediatric Pulmonology ; 57:S35-S36, 2022.

Article in English | Web of Science | ID: covidwho-1912983

COVID-19 Pandemic and Dysbiosis: Can the Ivermectin Hysteria Lead to an Increase of Autoimmune Neuroinflammatory Diseases?

Peron, J P S; Nakaya, H I; Schlindwein, M A M; Gonçalves, Marcus Vinicius Magno.

Crit Rev Immunol ; 40(6): 537-542, 2020.

Article in English | MEDLINE | ID: covidwho-1050522

ABSTRACT

The pandemic caused by the SARS-CoV-2 has made new treatments a goal for the scientific community. One of these treatments is Ivermectin. Here we discuss the hypothesis of dysbiosis caused by the use of Ivermectin and the possible impacts on neuroinflammatory diseases after the end of the pandemic.

Subject(s)

COVID-19/epidemiology , COVID-19/virology , Dysbiosis/epidemiology , SARS-CoV-2 , Autoimmune Diseases of the Nervous System/epidemiology , Autoimmune Diseases of the Nervous System/etiology , COVID-19/complications , Disease Susceptibility , Dysbiosis/etiology , Humans , Ivermectin/adverse effects , Ivermectin/therapeutic use , SARS-CoV-2/drug effects , SARS-CoV-2/immunology , COVID-19 Drug Treatment

ABSTRACT

Subject(s)

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL